Sat.Jul 03, 2021 - Fri.Jul 09, 2021

article thumbnail

Digital brain biomarker company Monument Therapeutics raises £2.6 million

Drug Discovery Today

Cambridge Cognition spin-out targets schizophrenia and post-operative cognitive dysfunction

113
113
article thumbnail

New patent expiration for Sucampo Pharma drug RESCULA

Drug Patent Watch

Annual Drug Patent Expirations for RESCULA Rescula is a drug marketed by Sucampo Pharma Llc and is included in one NDA. There is one patent protecting this drug and one…. The post New patent expiration for Sucampo Pharma drug RESCULA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Biogen to Report Second Quarter 2021 Financial Results July 22, 2021

The Pharma Data

Biogen Inc. (Nasdaq:BIIB) today announced it will report second quarter 2021 financial results Thursday, July 22, 2021, before the financial markets open. Following the release of the financials, the Company will host a live webcast with Biogen management at 8:00 a.m. ET. To access the live webcast, please go to the investors section of Biogen’s website at investors.biogen.com.

article thumbnail

Understanding The Signs & Symptoms Of Social Anxiety

Olympian Clinical Research

Social anxiety disorder, sometimes referred to as a social phobia, is a type of anxiety disorder characterized by extreme fear, distress, and anxiety in social settings. It’s important to note that being naturally more shy, reserved, or introverted is not the same thing as having social anxiety. While people with social anxiety may or may not exhibit shyness in social situations, it’s the uncontrollable fear, anxiety, and subsequent avoidance of social situations that differentiates someone with

article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

The Current issue of “The view from here” is concerned with Cardiovascular Drugs

Drug Discovery Today

The topic of this month’s newsletter from Drug Discovery Today is “Cardiovascular Drugs”.

Drugs 113
article thumbnail

New patent for Optinose Us drug XHANCE

Drug Patent Watch

Annual Drug Patent Expirations for XHANCE Xhance is a drug marketed by Optinose Us Inc and is included in one NDA. There are thirteen patents protecting this drug. XHANCE drug…. The post New patent for Optinose Us drug XHANCE appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 98

More Trending

article thumbnail

Preclinical Models for Bispecific T Cell Engager Development

Crown Bioscience

Last month we hosted a webinar with Dr. Ludovic Bourré, Senior Director of Scientific Engagement at Crown Bioscience, focused on the next generation of preclinical models advancing bispecific T cell engager (BiTE) development.

52
article thumbnail

Rite Aid’s PBM Strategy: Will Hope Triumph Over Experience?

Drug Channels

ICYMI, Rite Aid recently released the financial results for its most recent fiscal quarter, which ended on May 29. Rite Aid’s pharmacy benefit manager (PBM) business, Elixir, continues to flail in an increasingly challenging market. I’ve long been skeptical of Rite Aid’s PBM strategy. As you will see below, last quarter’s results further validated my skepticism.

article thumbnail

New patent expiration for Astellas drug MYCAMINE

Drug Patent Watch

Annual Drug Patent Expirations for MYCAMINE Mycamine is a drug marketed by Astellas and is included in one NDA. It is available from one supplier. There is one patent protecting…. The post New patent expiration for Astellas drug MYCAMINE appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 98
article thumbnail

mRNA vaccines slash risk of COVID-19 infection by 91% in fully vaccinated people

The Pharma Data

People who receive mRNA COVID-19 vaccines are up to 91 percent less likely to develop the disease than those who are unvaccinated, according to a new nationwide study of eight sites, including Salt Lake City. For those few vaccinated people who do still get an infection, or “breakthrough” cases, the study suggests that vaccines reduce the severity of COVID-19 symptoms and shorten its duration.

Vaccine 52
article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

article thumbnail

Automatic Analog Generation With Common R-group Replacements

Practical Cheminformatics

Another pointer to the FastPages site

40
article thumbnail

Importance of FDA Combination Products

Pharmaceutical Development Group

Introduction FDA (can also be expanded as the Food and Drug Administration) is a bureau that administers the public’s welfare by controlling and surveillance of food products, medications, vaccines, medical devices, etc. There are certain rules and criteria for post marketing safety reporting of FDA combination products. What are combination products?

article thumbnail

New patent expiration for Allergan drug ALPHAGAN P

Drug Patent Watch

Annual Drug Patent Expirations for ALPHAGAN+P Alphagan P is a drug marketed by Allergan and is included in two NDAs. It is available from one supplier. There are eight patents…. The post New patent expiration for Allergan drug ALPHAGAN P appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

Notice Concerning Issuance of New Shares under the Long-Term Incentive Plan for Company Group Employees Overseas

The Pharma Data

Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Company”) today announced that it decided to issue new shares (“Issuance of New Shares”) under the Long Term Incentive Plan (“LTIP”) for the Company Group employees overseas, as outlined below. Outline of issuance (1) Payment dateJuly 26, 2021(2) Type and number of shares to be issuedShares of common stock in the Company; numbering 3,874,305 shares(3) Issuance price3,685 yen per share(4) Total value of shar

article thumbnail

Clinical Data Like You´ve Never Seen It Before: Why Spotfire Is the Leading Tool for Clinical Analytics

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

article thumbnail

New patent expiration for Astrazeneca drug BRILINTA

Drug Patent Watch

Annual Drug Patent Expirations for BRILINTA Brilinta is a drug marketed by Astrazeneca and is included in one NDA. It is available from two suppliers. There are four patents protecting…. The post New patent expiration for Astrazeneca drug BRILINTA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

New patent expiration for Astrazeneca drug FASLODEX

Drug Patent Watch

Annual Drug Patent Expirations for FASLODEX Faslodex is a drug marketed by Astrazeneca and is included in one NDA. It is available from one supplier. There are four patents protecting…. The post New patent expiration for Astrazeneca drug FASLODEX appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

New patent expiration for Nabriva drug XENLETA

Drug Patent Watch

Annual Drug Patent Expirations for XENLETA Xenleta is a drug marketed by Nabriva and is included in two NDAs. There are four patents protecting this drug. Drug patent litigation for…. The post New patent expiration for Nabriva drug XENLETA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

New patent for Myovant Sciences drug MYFEMBREE

Drug Patent Watch

Annual Drug Patent Expirations for MYFEMBREE Myfembree is a drug marketed by Myovant Sciences and is included in one NDA. The generic ingredient in MYFEMBREE is estradiol; norethindrone acetate; relugolix.…. The post New patent for Myovant Sciences drug MYFEMBREE appeared first on DrugPatentWatch - Make Better Decisions.

Science 52
article thumbnail

New patent for Arbor Pharms drug EVEKEO ODT

Drug Patent Watch

Annual Drug Patent Expirations for EVEKEO+ODT Evekeo Odt is a drug marketed by Arbor Pharms Llc and is included in one NDA. It is available from one supplier. There are…. The post New patent for Arbor Pharms drug EVEKEO ODT appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

AbbVie to Host Second-Quarter 2021 Earnings Conference Call

The Pharma Data

AbbVie (NYSE: ABBV) will announce its second-quarter 2021 financial results on Friday, July 30, 2021, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie’s Investor Relations website investors.abbvie.com. An archived edition of the session will be available later that day.

article thumbnail

New patent for DUSA drug LEVULAN

Drug Patent Watch

Annual Drug Patent Expirations for LEVULAN Levulan is a drug marketed by Dusa and is included in one NDA. It is available from one supplier. There is one patent protecting…. The post New patent for DUSA drug LEVULAN appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

New patent for Braintree Labs drug SUTAB (COPACKAGED)

Drug Patent Watch

Annual Drug Patent Expirations for SUTAB+%28COPACKAGED%29 Sutab (copackaged) is a drug marketed by Braintree Labs and is included in one NDA. It is available from one supplier. There is one…. The post New patent for Braintree Labs drug SUTAB (COPACKAGED) appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

New patent for APGDI drug MYRBETRIQ GRANULES

Drug Patent Watch

Annual Drug Patent Expirations for MYRBETRIQ+GRANULES Myrbetriq Granules is a drug marketed by Apgdi and is included in one NDA. It is available from one supplier. There are four patents…. The post New patent for APGDI drug MYRBETRIQ GRANULES appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

Researchers find potential path to a broadly protective COVID-19 vaccine using T cells

The Pharma Data

Gaurav Gaiha, MD, DPhil, a member of the Ragon Institute of MGH, MIT and Harvard, studies HIV, one of the fastest-mutating viruses known to humankind. But HIV’s ability to mutate isn’t unique among RNA viruses – most viruses develop mutations, or changes in their genetic code, over time. If a virus is disease-causing, the right mutation can allow the virus to escape the immune response by changing the viral pieces the immune system uses to recognize the virus as a threat, piece

Vaccine 52
article thumbnail

Cancer cells eat themselves to survive

The Pharma Data

It is the membrane of cancer cells that is at the focus of the new research now showing a completely new way in which cancer cells can repair the damage that can otherwise kill them. In both normal cells and cancer cells, the cell membrane acts as the skin of the cells. And damage to the membrane can be life threatening. The interior of cells is fluid, and if a hole is made in the membrane, the cell simply floats out and dies – a bit like a hole in a water balloon.

article thumbnail

Sanofi highlights scientific innovations in the field of rare blood disorders at ISTH 2021

The Pharma Data

Sanofi highlights scientific innovations in the field of rare blood disorders at I STH 2021. New research from first-in-class marketed and investigational therapies in hemophilia, immune thrombocytopenia and acquired thrombotic thrombocytopenic purpura will be presented. Clinical data and new research from Sanofi’s rare blood disorders portfolio of marketed and investigational therapies for people with hemophilia, immune thrombocytopenia (ITP) and acquired thrombotic thrombocytopenic purpura (aT

article thumbnail

AstraZeneca receives clearance from the European Commission for the proposed acquisition of Alexion

The Pharma Data

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION. THIS IS AN ANNOUNCEMENT AND NOT A CIRCULAR OR PROSPECTUS OR EQUIVALENT DOCUMENT FOR THE PURPOSES OF THE UK PROSPECTUS REGULATION RULES OR THE UK AND EU PROSPECTUS REGULATIONS.

article thumbnail

Bayer opens application window for Grants4Ag sustainability-focused program

The Pharma Data

Program awards researchers and scientists for sustainable solutions to agricultural challenges / Selected grant winners receive both financial prize and mentorship from industry leaders. Bayer announced today the opening of its application window for the company’s annual Grants4Ag initiative. For more than five years, the agricultural leader has offered researchers both financial and scientific support to develop their ideas for novel solutions to research and development challenges in agricultu

Science 52
article thumbnail

Drug Patent Expirations for the Week of July 4, 2021

Drug Patent Watch

FASLODEX (fulvestrant) Astrazeneca Patent: 7,456,160 Expiration: Jul 9, 2021 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit…. The post Drug Patent Expirations for the Week of July 4, 2021 appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 40
article thumbnail

Which pharmaceutical companies have the most drug patents in Poland?

Drug Patent Watch

This chart shows the pharmaceutical companies with the most patents in Poland. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Poland? appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

Which pharmaceutical drugs have the most drug patents in Greece?

Drug Patent Watch

This chart shows the drugs with the most patents in Greece. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Greece? appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

Which pharmaceutical companies have the most insert dosed drugs?

Drug Patent Watch

This chart shows the pharmaceutical companies with the most insert dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most insert dosed drugs…. The post Which pharmaceutical companies have the most insert dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

Which pharmaceutical drugs have the most drug patents in Eurasian Patent Organization?

Drug Patent Watch

This chart shows the drugs with the most patents in Eurasian Patent Organization. Patents must be filed in each country (or, in some cases regional patent office) where patent protection…. The post Which pharmaceutical drugs have the most drug patents in Eurasian Patent Organization? appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

Which pharmaceutical companies have the most gas dosed drugs?

Drug Patent Watch

This chart shows the pharmaceutical companies with the most gas dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most gas dosed drugs…. The post Which pharmaceutical companies have the most gas dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.